Jbf Capital Exits Position in Xenon Pharmaceuticals Inc (XENE)

Xenon Pharmaceuticals Inc (XENE) : Jbf Capital has sold out all of its stake in Xenon Pharmaceuticals Inc during the most recent quarter, according to the disclosure filed by the company on Aug 8, 2016 with the SEC. The investment management company has sold out 68,690 shares of Xenon Pharmaceuticals Inc which is valued at $537,843.

Other Hedge Funds, Including , Gsa Capital Partners Llp sold out all of its stake in XENE during the most recent quarter. The investment firm sold 13,384 shares of XENE which is valued $99,845.

Xenon Pharmaceuticals Inc opened for trading at $7.9402 and hit $8.5 on the upside on Monday, eventually ending the session at $8.38, with a gain of 4.88% or 0.39 points. The heightened volatility saw the trading volume jump to 7,582 shares. Company has a market cap of $121 M.

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company has built a core platform Extreme Genetics enabling the discovery of validated drug targets by studying rare human diseases with extreme traits including diseases caused by mutations in ion channels known as channelopathies. Its product pipeline includes Glybera which is a gene therapy approved in the EU for the treatment of patients with the orphan lipid disorder LPLD; TV-45070 which is a small-molecule inhibitor of the sodium channel Nav1.7; GDC-0276 which is a selective oral Nav1.7 small-molecule inhibitor being developed for the treatment of pain and XEN801 which is a selective small molecule inhibitor of SCD1 being developed for the treatment of dermatological disorders. FDA has granted fast track designations to TV-45070 for EM and to Glybera for LPLD and received orphan drug designation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *